GHIC Portfolio Company Antheia Raises Additional $24 Million, Bringing Series C to $80 Million Funded

New York, NY — Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, announced a second close of its Series C financing, raising an additional $24 million and bringing the total Series C to $80 million funded.

The Series C financing was initially led by Global Health Investment Corporation (GHIC) and EDBI, who partnered to bring together a strong group of mission-aligned investors to support Antheia’s vision for transforming pharmaceutical supply chains. The second close was led by ATHOS KG and America’s Frontier Fund, with continued participation from existing investors, including GHIC.

Proceeds from the Series C financing will be used to expand Antheia’s commercial manufacturing capacity, advance the company’s robust pipeline of late-stage biosynthetic pharmaceutical ingredients toward commercialization, and establish U.S. manufacturing operations aligned with national onshoring priorities.

“Advanced biosynthesis has immense potential to transform pharmaceutical supply chains and unlock a new era of innovative medicines,” said Dr. Christina Smolke, CEO and co-founder of Antheia. “Building on the success of our Series C, this additional infusion of capital will fuel our efforts to address urgent supply chain vulnerabilities and more broadly, lead a paradigm shift for pharmaceutical manufacturing.”

Today’s announcement follows several major milestones across 2024 and 2025, including Antheia’s first commercial delivery of thebaine—the key ingredient used to produce Narcan—as well as two U.S. government project agreements to onshore pharmaceutical supply chains. In November 2025, Antheia also announced a strategic partnership with TAPI to further commercialize its pipeline.

About Antheia:

Antheia is the advanced biosynthesis company transforming pharmaceutical manufacturing and innovation for the 21st century. Antheia’s commercially proven technology platform produces high-value pharmaceutical ingredients in a fraction of the time compared to legacy approaches while significantly reducing supply chain risk. The company provides its global pharmaceutical customers with a resilient, efficient supply of critical ingredients at scale, while expanding the innovation frontier for new therapeutic development. Backed by leading investors and recognized by the U.S. government as a priority technology for public health and national and economic security, Antheia is manufacturing the medicines the world needs today while enabling tomorrow’s breakthrough therapeutics. For more information, visit www.antheia.bio.

About Global Health Investment Corporation (GHIC)

A pioneer of investing in global health, GHIC has been supporting high-impact biomedical innovations for nearly a decade. GHIC's Global Health Investment Fund (GHIF) financed the development of products to combat public health challenges that disproportionately affect people living in low- and middle-income countries. In 2021, GHIC entered a 10-year venture investment partnership with the Biomedical Advanced Research and Development Authority (BARDA) focused on global health security.